NEW YORK (GenomeWeb News) – Sequenom today disclosed that it has entered into a cease-and-desist order with the US Securities and Exchange Commission related to previous public statements regarding its trisomy 21 test, but it will not have to pay any monetary penalties to the commission.
The cease-and-desist order specifically applies to public statements the firm had made during the period between January 2008 and June 2009 related to development of its trisomy 21 molecular test. Sequenom has agreed "not to commit or to cause any future violations of Sections 10(b) and 13(a) of the Exchange Act," and rules under those sections, it said in a filing with the SEC. Section 10(b) prohibits fraud, manipulation, and insider trading, while Section 13(a) covers rules regarding the filing of periodic reports with the SEC.
A subsequent investigation by Sequenom's board of directors led to the dismissal of President and CEO Harry Stylli and Senior VP of R&D Elizabeth Dragon, among others, from the firm in September 2009.
With new management at the helm, Sequenom has since continued development of the sequencing-based test, now called MaterniT21. During its second-quarter conference call early last month Chairman and CEO Harry Hixson said the firm still intends to launch a T21 laboratory developed test following the publication of clinical data on the test, which is expected in late 2011 or early 2012. He added that a manuscript has been submitted to journal but has not yet been accepted.